Bishal Gyawali, Medical Oncologist at Professor at Queen’s University, shared a post on X:
“You’ve seen me advocate again and again against the use of downplaying terms to describe toxicities in cancer clinical trials.
Do you want to see an example of why I’m so passionate about this? Look at these results.
Denominator is 50 patients. So this is 2% death from cardiogenic shock and 2% grade 3 autoimmune hepatitis. Guess what the safety conclusion of this trial is?
I don’t know the definition of manageable anymore.
Title: Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial
Authors: Samer Srour, Jad Chahoud, Alexandra Drakaki, Brendan Curti, Geoffrey Gibney, Lily Tang, Yizhou Jiang, Sara Charmsaz, Paul Robbins, Jeff McLeroy, Christopher Severyn, John Le Gall, Zachary Roberts, Nizar Tannir, Sumanta Pal, Ritesh Kotecha
Read the Full Article on Journal of Clinical Oncology
Other posts featuring Bishal Gyawali on OncoDaily.